<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03197818</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-5993AA1-14</org_study_id>
    <secondary_id>China</secondary_id>
    <secondary_id>Taiwan</secondary_id>
    <secondary_id>South Korea</secondary_id>
    <nct_id>NCT03197818</nct_id>
  </id_info>
  <brief_title>Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)</brief_title>
  <acronym>TRIVERSYTI</acronym>
  <official_title>A 24-week, Double Blind, Double Dummy, Randomized, Multinational, Multicentre, 2-arm Parallel Group,Active Controlled Clinical Trial of Fixed Combination of Beclometasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide Administered Via pMDI (CHF 5993) Versus the Fixed Combination of Budesonide Plus Formoterol Fumarate (Symbicort® Turbuhaler®) in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the superiority of CHF 5993 pMDI (fixed
      combination of extrafine beclometasone dipropionate plus formoterol fumarate plus
      glycopyrronium bromide) over Symbicort® Turbuhaler® in terms of pulmonary function, as well
      as to assess its safety.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in pre-dose FEV1(Forced Expiratory Volume within the first second) at week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from Baseline in pre-dose FEV1(Forced Expiratory Volume within the first second) at week 24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in 2-hour post-dose FEV1 at week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from Baseline in 2-hour post-dose FEV1 at week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in pre-dose morning FEV1 and 2-hour post-dose morning FEV1 at week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from Baseline in pre-dose morning FEV1 and 2-hour post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First COPD exacerbation</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>Time to First COPD exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of COPD exacerbations</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>Rate of COPD exacerbations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in COPD Assessment Test (CAT)</measure>
    <time_frame>At all visits (from baseline to Week 24)</time_frame>
    <description>Change in COPD Assessment Test (CAT)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events and Adverse Drug reactions</measure>
    <time_frame>Screening up to week 24</time_frame>
    <description>Adverse Events and Adverse Drug reactions</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">990</enrollment>
  <condition>COPD (Chronic Obstructive Pulmonary Disease)</condition>
  <arm_group>
    <arm_group_label>CHF 5993 100/6/12.5 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose (BDP/FF/GB) (Beclometasone dipropionate / Formoterol Fumarate / glycoppyronium Bromide)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort Turbuhaler 160/4.5 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (160µg + 4.5 µg expresses the delivered dose; 200 µg + 6 µg expresses the metered dose) ( BUD/FF) (Budesonide/Formoterol Fumarate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 100/6/12.5 µg</intervention_name>
    <description>Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose</description>
    <arm_group_label>CHF 5993 100/6/12.5 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>160 µg budesonide + 4.5 µg formoterol fumarate</intervention_name>
    <description>Fixed combination of budesonide 160 µg plus formoterol fumarate 4.5 µg</description>
    <arm_group_label>Symbicort Turbuhaler 160/4.5 µg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female adults aged &gt; 40 years with a diagnosis of COPD

          -  Current smokers or ex-smokers

          -  A post-bronchodilator FEV1 &lt; 50% of the predicted normal value and a
             post-bronchodilator FEV1/FVC ratio &lt; 0.7 at least 10-15 minutes after 4 puffs (4 x 100
             µg) of salbutamol pMDI

          -  At least one exacerbation in the 12 months preceding the screening visit

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Diagnosis of asthma, history of allergic rhinitis or atopy

          -  Patients treated for exacerbations in the 4 weeks prior to screening visit

          -  Patients treated with non-cardioselective ß-blockers in the month preceding the
             screening visit

          -  Patients treated with long-acting antihistamines unless taken at stable regimen at
             least 2 months prior to screening and to be maintained constant during the study or if
             taken as Pro Re Nata

          -  Patients requiring long term ( at least 12 hours daily) oxygen therapy for chronic
             hypoxemia

          -  Known respiratory disorders other than COPD

          -  Patients who have clinically significant cardiovascular condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinping Zheng</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chiesi Clinical Trial Info</last_name>
    <email>clinicaltrials_info@chiesi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chiesi clinical Trial Site 156031</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 156026</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial Site 156017</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial Site 156022</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 156016</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 156012</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100144</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 156002</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial Site 156024</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <zip>528000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 156013</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University site 156001</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingping Zheng</last_name>
      <phone>+86-20-8333-7750</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 156008</name>
      <address>
        <city>Zhanjiang</city>
        <state>Guangdong</state>
        <zip>524000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 156003</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial Site 156020</name>
      <address>
        <city>Haikou Shi</city>
        <state>Hainan</state>
        <zip>570100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 156040</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 156015</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <zip>014010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 156004</name>
      <address>
        <city>Huai'an</city>
        <state>Jiangsu</state>
        <zip>223300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial Site 156033</name>
      <address>
        <city>Jiangyin</city>
        <state>Jiangsu</state>
        <zip>320281</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 156038</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial Site 156028</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial Site 156023</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial Site 156019</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 156007</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial Site 156025</name>
      <address>
        <city>YinChuan</city>
        <state>Ningxia</state>
        <zip>750000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial Site 156027</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250033</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 156014</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial Site 156037</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 156005</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 156006</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 156011</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 156039</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial Site 156035</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 156010</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial Site 156032</name>
      <address>
        <city>Chongqing</city>
        <state>Sichuan</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial Site 156034</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial Site 156018</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 410003</name>
      <address>
        <city>ChunCheon-si</city>
        <state>Gang'weondo</state>
        <zip>24289</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 410001</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggido</state>
        <zip>420-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 410002</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggido</state>
        <zip>10380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 410005</name>
      <address>
        <city>Jeonju-si</city>
        <state>Jeonrabugdo</state>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 410008</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>07345</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 410007</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>07985</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 410004</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>100-032</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 410006</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 410009</name>
      <address>
        <city>Gangnam-gu</city>
        <state>Seoul Teugbyeols</state>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 410010</name>
      <address>
        <city>Nam-gu</city>
        <state>Ulsan</state>
        <zip>705-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 158001</name>
      <address>
        <city>Keelung</city>
        <state>Keelung Municipality</state>
        <zip>204</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 158004</name>
      <address>
        <city>Kaohsiung</city>
        <state>Penghu</state>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 158002</name>
      <address>
        <city>Yongkang</city>
        <state>Tainan</state>
        <zip>71044</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 158010</name>
      <address>
        <city>Changhua</city>
        <state>Taiwan province</state>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 158003</name>
      <address>
        <city>Douliou</city>
        <state>Yunlin</state>
        <zip>64041</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 158006</name>
      <address>
        <city>Kaohsiung</city>
        <zip>824</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 158007</name>
      <address>
        <city>Taichung</city>
        <zip>40443</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 158008</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 158005</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 158009</name>
      <address>
        <city>Taipei</city>
        <zip>11696</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Anticholinergics</keyword>
  <keyword>Triple Combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

